cardiovascular
Transcend Plus includes AI-enabled clinical applications and FDA-cleared enhancements.
The financing comes on top of the company's $900 million annual research and development investment in the U.S.
The funding comes more than a year after the company closed an oversubscribed $31.4 million Series B round.